Growth Metrics

Beta Bionics (BBNX) Asset Writedowns and Impairment (2024 - 2025)

Beta Bionics recorded quarterly Asset Writedowns and Impairment of $16000.0 in Q4 2025, down 33.33% quarter-over-quarter from $24000.0 in Q3 2025, and down 38.46% year-over-year from $26000.0 in Q4 2024.

Beta Bionics' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $16000.0 for Q4 2025.

  • In Q4 2025, Asset Writedowns and Impairment fell 38.46% year-over-year to $16000.0; the TTM figure through Dec 2025 stood at $40000.0 (down 42.86% YoY), while the FY2025 annual figure was $40000.0, down 42.86% from the prior year.
  • Asset Writedowns and Impairment came in at $16000.0 for Q4 2025 at Beta Bionics, down from $24000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $27000.0 in Q2 2024 to a low of $16000.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Beta Bionics 572.34 Mn 542.03 Mn 16.44 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 16,000.00
Dec 31, 2025 16,000.00
Sep 30, 2025 24,000.00
Sep 30, 2025 24,000.00
Dec 31, 2024 26,000.00
Dec 31, 2024 26,000.00
Jun 30, 2024 27,000.00
Jun 30, 2024 27,000.00
Mar 31, 2024 17,000.00
Mar 31, 2024 17,000.00